Gilead Sciences Reports Publication of Phase 3 Trial Results of Trodelvy and Keytruda for Breast Cancer

MT Newswires Live01-22

Gilead Sciences (GILD) said late Wednesday that The New England Journal of Medicine published full results from its phase 3 trial of Trodelvy and Keytruda for first-line PD-L1+ metastatic triple-negative breast cancer that met its primary endpoint of progression-free survival, with a 35% reduced risk of disease progression or death compared with Keytruda plus chemotherapy treatment.

Median PFS with Trodelvy plus Keytruda was 11.2 months compared with 7.8 months for Keytruda in combination with chemotherapy, the company said.

The safety profile of the drug regimen was consistent with the known safety profile of each agent, and no new safety signals were identified, according to a statement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment